RxDoctor Payments Data

Priti Palvadi, MD

Neurology · Pasadena, TXNPI 1700992641

Payments from drug & device makers

$9,403in general payments, 2019–2025

Across 512 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novartis$858
  • EMD Serono, Inc.$651
  • Sunovion Pharmaceuticals Inc.$476
  • AstraZeneca$420
  • Biogen$351
  • plus $6K from 54 others

What the payments were for

  • Speaking & faculty fees$1992%
  • Food & beverage$9,20398%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)92$1,007
Novartis57$858
EMD Serono, Inc.30$651
Sunovion Pharmaceuticals Inc.36$476
AstraZeneca15$420
Biogen16$351
Harmony Biosciences LLC23$334
Jazz Pharmaceuticals Inc.13$302
Acadia Pharmaceuticals Inc13$239
Neurocrine Biosciences, Inc.10$238
Pfizer10$229
Lundbeck LLC10$210
SK Life Science, Inc.8$208
Otsuka America Pharmaceutical, Inc.8$202
Acorda Therapeutics, Inc9$199
Argenx US, Inc.7$193
Assertio Therapeutics, Inc.12$185
CSL Behring7$172
UCB, Inc.5$144
Abbott5$140
Adamas Pharmaceuticals, Inc.6$138
Lilly USA, LLC8$123
Inspire Medical Systems, Inc.5$113
Teva Pharmaceuticals USA, Inc.6$103
Mallinckrodt Hospital Products Inc.5$101
Johnson & Johnson2$100
Sanofi6$99
Genentech USA, Inc.4$95
Springworks Therapeutics, Inc.4$91
Livanova USA, Inc.4$85
Supernus Pharmaceuticals, Inc.6$85
GE HealthCare3$84
Sumitomo Pharma America, Inc.7$78
Octapharma USA, Inc.1$77
Amneal Pharmaceuticals LLC4$76
ANI Pharmaceuticals, Inc.3$75
Axsome Therapeutics, Inc.3$72
Tanabe Pharma America, Inc.4$71
Boston Scientific2$71
Kyowa Kirin, Inc.3$68
Upsher-smith Laboratories LLC4$66
Avadel CNS Pharmaceuticals, LLC2$60
Corium, LLC2$60
Merz North America, Inc.2$48
Merz Pharmaceuticals, LLC2$47
Amgen2$44
Promius Pharma LLC2$37
Grifols USA, LLC2$36
Azurity Pharmaceuticals, Inc.2$34
Eisai Inc.2$33
Sandoz1$33
Arbor Pharmaceuticals, Inc.2$32
Avanir Pharmaceuticals, Inc.2$32
Ipsen Biopharmaceuticals, Inc1$29
Akcea Therapeutics, Inc.1$28
Insightec,inc2$28
Biotronik NRO, Inc.1$28
Biohaven Pharmaceutical Holding Company Ltd.1$26
Nevro Corp.1$25
Shire North American Group Inc1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,403 in reported general payments places this provider in the 65th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$171,408
Medicare patients
268
Services billed
6,852

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate23$130,709
RexultiBrexpiprazole39$64,223
SunosiSolriamfetol Hcl14$23,088
AptiomEslicarbazepine Acetate15$18,502
BotoxOnabotulinumtoxina12$15,727
Topiramate ErTopiramate12$13,101
RytaryCarbidopa/Levodopa11$11,364
Memantine Hcl359$9,414
Rasagiline Mesylate29$8,163
Memantine Hcl ErMemantine Hcl57$7,474
Levetiracetam143$7,429
Gabapentin346$7,062
Carbidopa-LevodopaCarbidopa/Levodopa144$6,191
Pyridostigmine Bromide15$5,579
Rivastigmine22$5,443

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$103$130,70923 claims
Otsuka America Pharmaceutical, Inc.Rexulti$202$64,22339 claims
Axsome Therapeutics, Inc.Sunosi$72$23,08814 claims
Sunovion Pharmaceuticals Inc.Aptiom$476$18,50215 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$76$16,94326 claims
AbbVieBotox$1,007$15,72712 claims
PfizerDilantin$229$3,81615 claims
Upsher-smith Laboratories LLCTopiramate$66$2,112232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,246 neurology providers in Texas.

Other neurology in Pasadena

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →